HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 277, Issue 19, 16814-16822, May 10, 2002

This Article Abstract Full Text (PDF) All Versions of this Article: 277/19/16814    most recent M112349200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rayner, T. F. Articles by Thorner, J. W. Search for Related Content PubMed PubMed Citation Articles by Rayner, T. F. Articles by Thorner, J. W. Social Bookmarking                      What's this?

Direct and Novel Regulation of cAMP-dependent Protein Kinase by Mck1p, a Yeast Glycogen Synthase Kinase-3^*

Timothy F. Rayner^§¶, Joseph V. Gray^§, and Jeremy W. Thorner

From the  Department of Molecular and Cell Biology, Division of Biochemistry and Molecular Biology, University of California, Berkeley, California 94720-3202 and the ^§ Division of Molecular Genetics, Faculty of Biomedical and Life Sciences, University of Glasgow, Robertson Bldg., Anderson College Complex, 54-56 Dumbarton Rd., Glasgow G11 6NU, United Kingdom

Received for publication, December 24, 2001, and in revised form, February 17, 2002

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

The MCK1 gene of Saccharomyces cerevisiae encodes a protein kinase homologous to metazoan glycogen synthase kinase-3. Previous studies implicated Mck1p in negative regulation of pyruvate kinase. In this study we find that purified Mck1p does not phosphorylate pyruvate kinase, suggesting that the link is indirect. We find that purified Tpk1p, a cAMP-dependent protein kinase catalytic subunit, phosphorylates purified pyruvate kinase in vitro, and that loss of the cAMP-dependent protein kinase regulatory subunit, Bcy1p, increases pyruvate kinase activity in vivo. We find that purified Mck1p inhibits purified Tpk1p in vitro, in the presence or absence of Bcy1p. Mck1p must be catalytically active to inhibit Tpk1p, but Mck1p does not phosphorylate this target. We find that abolition of Mck1p autophosphorylation on tyrosine prevents the kinase from efficiently phosphorylating exogenous substrates, but does not block its ability to inhibit Tpk1p in vitro. We find that this mutant form of Mck1p appears to retain the ability to negatively regulate cAMP-dependent protein kinase in vivo. We propose that Mck1p, in addition to phosphorylating some target proteins, also acts by a separate, novel mechanism: autophosphorylated Mck1p binds to and directly inhibits, but does not phosphorylate, the catalytic subunits of cAMP-dependent protein kinase.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

The genome of Saccharomyces cerevisiae encodes four different protein kinases highly similar (greater than 40% identity) to mammalian glycogen synthase kinase-3 (GSK-3)¹ (1). One of these kinases is encoded by MCK1 (2, 3). Like its vertebrate homologues, Mck1p displays dual specificity in vitro, in that it is capable of autophosphorylating on serine and tyrosine residues, but only phosphorylates exogenous substrates on serine and threonine (3).

The protein kinases of the glycogen synthase kinase-3 (GSK-3) sub-family have been implicated in a variety of regulatory processes. In mammals, the prototypic members, GSK-3 and GSK-3, phosphorylate and are thought to regulate a number of metabolic enzymes (4-7). GSK-3 enzymes are intimately involved in the insulin signaling pathway and in key developmental pathways in a number of organisms (8, 9). The development of the dorsal-ventral axis in Drosophila and Xenopus embryos relies on the function of the Wingless/Wnt pathway. GSK-3 is inhibited by this pathway, allowing the expression of crucial developmental genes (9).

Yeast cells lacking Mck1p display a wide range of phenotypes, indicating that Mck1p may have multiple targets. Deletion of the MCK1 locus results in various defects in carbon metabolism, including reduced glycogen accumulation and poor growth on non-fermentable carbon sources (10, 11). Other phenotypes resulting from deletion of MCK1 include heat and cold sensitivity (10, 12), delayed sporulation (13) and sensitivity to the microtubule-destabilizing drug benomyl (12). In this work we show that mck1 cells are also sensitive to caffeine. Overexpression of MCK1 has been shown to suppress temperature-sensitive mutations in CBF2 and CBF5, which encode essential centromere-binding proteins. Mck1p was found to bind to and phosphorylate Cbf2p in vitro (14, 15). More recently, MCK1 and RIM11 have been implicated in the protein ubiquitination pathway (16). Finally, MCK1 has been implicated in the response to high concentrations of NaCl in growth medium (17).

Previous work has demonstrated that Mck1p down-regulates pyruvate kinase (EC 2.7.1.40), encoded by the CDC19/PYK1 gene, in vivo (11). Like mck1 mutants, strains overproducing pyruvate kinase fail to grow at 37 °C and do not accumulate normal amounts of glycogen. Cells overexpressing CDC19, like mck1, adapt poorly to growth on non-fermentable carbon sources (11, 18, 19). Finally, diploid cells overexpressing CDC19 show markedly diminished sporulation efficiency (11), similar to that observed in mck1/mck1 diploids. Deletion of MCK1 was found to exacerbate each of these CDC19 overexpression phenotypes (11).

The findings of Brazill et al. (11) suggested that Mck1p might directly phosphorylate pyruvate kinase, thereby down-regulating the activity of this enzyme. In this report we investigate this possibility. We find that Mck1p does not in fact phosphorylate pyruvate kinase but instead acts to inhibit an intermediary kinase, which would otherwise phosphorylate the glycolytic enzyme. We identify this intermediary kinase as cAMP-dependent protein kinase (PKA). The genome of S. cerevisiae contains three genes encoding PKA catalytic subunits, TPK1, TPK2, and TPK3, and one gene, BCY1, encoding the cAMP binding and negative regulatory subunit of PKA. A purified Tpk1p·Bcy1p complex phosphorylates purified pyruvate kinase, and this phosphorylation is stimulated by cAMP. Consistent with this result, we find that loss of Bcy1p increases pyruvate kinase activity in vivo. Phosphorylation of pyruvate kinase by Tpk1p·Bcy1p is inhibited by the addition of purified Mck1p in vitro. Mck1p also inhibits purified Tpk1p alone. This inhibition is dependent on Mck1p catalytic activity, but Mck1p does not phosphorylate Tpk1p (or indeed Bcy1p) in vitro. Mck1p autophosphorylation on tyrosine-199 is required for efficient phosphorylation of exogenous substrates but not for Mck1p autophosphorylation on other residues or for inhibition of Tpk1p in vitro. Finally, autophosphorylation by Mck1p on tyrosine (and hence phosphorylation of exogenous substrates) is not required for the regulation of PKA by Mck1p in vivo. We propose that, in addition to phosphorylating some target proteins, Mck1p also directly binds to and inhibits, but does not phosphorylate, the catalytic subunits of PKA.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Chemicals and Materials-- Purified bovine brain myelin basic protein (MBP), cAMP, LRRASLG (Kemptide), PKI, L-lactate dehydrogenase, DEAE-Sephadex, CM-Sephadex, and cAMP-agarose were purchased from Sigma-Aldrich Co. (St. Louis, MO). S-Sepharose was purchased from Amersham Biosciences, Inc. (Peapack, NJ). Nickel-agarose was purchased from Novagen (Madison, WI) and prepared according to the manufacturer's instructions. Anti-His₆ tag antibodies were purchased from Covance Research Products (Richmond, CA). Anti-phosphotyrosine monoclonal antibody clone 4G10 was purchased from Upstate Biotechnology Inc. (Lake Placid, NY). Modified Bradford protein concentration assay reagent was purchased from Bio-Rad Laboratories Inc. (Hercules, CA).

Partially purified pyruvate kinase was a gift of Tom Nowak (University of Notre Dame, Notre Dame, IN) and fully purified pyruvate kinase was generously provided by Barry Stoddard (Fred Hutchinson Cancer Research Center, Seattle, WA).

Growth of Yeast Cells-- Yeast strains were grown in YPD medium (1% yeast extract, 2% peptone, 2% glucose) (20) where appropriate. Selection for plasmid maintenance was provided where necessary by growing strains in synthetic minimal medium supplemented with the appropriate nutrients (20). Media containing non-fermentable carbon sources (acetate, glycerol, DL-lactate, or ethanol) were made by adding the relevant compound to suitable medium to a final concentration of 2%. In the cases of lactate and acetate, agar plates were made using unbuffered acids at 0.2%. All other plates contained 2% glucose as the carbon source. Agar plates contained 10 mM caffeine where indicated.

Plasmid Construction-- Standard molecular biology techniques were used in the construction of plasmids (21). All plasmids were sequenced to check for errors introduced in PCR and DNA ligation steps. Plasmid pDD7 is an MCK1 deletion construct in which the MCK1 open reading frame (ORF) has been disrupted with the URA3 gene flanked by direct repeats of the hisG gene (3). Plasmid pDD4 is a 2-µm plasmid based on YEp352 (22) encoding MCK1 under the control of its own promoter (3).

The ORF encoding C-terminal hexahistidine (His₆)-tagged Mck1p was constructed using a PCR-based approach consisting of two steps. The first step amplified the regions immediately flanking the 3'-end of the MCK1 ORF using plasmid pDD4 as a template. These reactions used two pairs of primers. Primer pUCforward (5'-GTT TTC CCA GTC ACG AC-3') was used with primer A (5'-CTC GAG TTA CGC GTG ATG ATG ATG ATG ATG TGA CGC GTC AGC AAC TTT CGT AGG TTT AAT TTT ATC-3') in one reaction, whereas the other reaction contained primer pUCreverse (5'-AGC GGA TAA CAA TTT CAC ACA GGA-3') and primer B (5'-CAT CAT CAC GCG TAA CTC GAG TAA TTT TCT ATT AAT TTG TTC TCT TTC C-3'). The second step in the construction of the His₆-tagged Mck1p construct combined the products of the first step and re-amplified the whole region using primers pUCforward and pUCreverse. The resultant full-length PCR product was cleaved with BstXI and PstI and subcloned into the corresponding sites in pDD4, producing plasmid pTRYMHU. The DNA sequence of this plasmid was confirmed to encode a protein incorporating the amino acid sequence Ser(His)₆Ala-CO₂H in place of the terminal glutamate residue of wild-type Mck1p. This plasmid was found to fully complement the mck1 mutation in vivo.²

Insertion of a BamHI site at the 5'-end of the MCK1 ORF was necessary to subclone the ORF downstream of the GAL promoter. The approach taken was similar to that for the insertion of the His₆ tag (above). The outlying primers in this case were primer pUCforward and primer C (5'-TTT ATT ATC TTG CGG GGA C-3'). The BamHI site was introduced using a primer with the sequence 5'-CTA GTA GGA TCC AAT ATG TCT ACG GAA GAG CAG AAT GGT GTT CC-3' and another primer complementary to this sequence. PCR reactions were performed as described for the generation of the His₆-tagged construct above. The final PCR product was digested with HindIII and BsrGI and subcloned into the corresponding sites in pTRYMHU to yield plasmid pTRYBMHU. The MCK1 ORF was then subcloned into plasmid YEp352GAL (23) by cleaving plasmid pTRYBMHU with BamHI and subcloning the 2-kb fragment bearing the MCK1 ORF into the BamHI site of YEp352GAL. The resulting plasmid was named pTRYGMHU.

The BCY1 ORF was cloned by PCR amplification using yeast genomic DNA as template and primers flanking the BCY1 locus (5'-TTA TCT CTC TCT GAT GAC GTG-3' and 5'-ATA TCA CGA TTA TAG TCG CAG C-3'). The resulting PCR product was cleaved with EcoRV and ScaI and subcloned into the EcoRV site of pRS423 (24) to generate plasmid YEpBCY1H. The BCY1 ORF was transferred to a 2-µm plasmid bearing the TRP1 marker by digesting the YEpBCY1H plasmid with XhoI and EcoRI and subcloning it into the corresponding sites of plasmid pRS424. The plasmid was finally cut with BamHI and SmaI, blunt-ended using Klenow DNA polymerase, and re-ligated to destroy these unwanted sites, yielding plasmid YEpBCY1.

A vector constitutively overexpressing histidine-tagged TPK1 was constructed in the following manner. The TPK1 locus was PCR-amplified from genomic DNA with the primers 5'-TGG ATC CAA TAT GTC GAC TGA AGA ACA AAA TGG AGG-3' and 5'-TAC TCG AGT TAC GCG TGA TGA TGA TGA TGA TGT GAC GCG AAG TCC CGG AAA AGA TCA GCA TAT GGG-3'. The ends of the PCR product were trimmed with BamHI, blunted with Klenow DNA polymerase, and cut again with XhoI. The resulting fragment was then subcloned into the SmaI-SalI sites of plasmid pAD4M (25), producing plasmid pTRYAT1HL.

Yeast Strains-- Standard molecular biology techniques were used in the construction of yeast strains (21). S. cerevisiae strains used in this work include YPH500 (MAT ura3-52 lys2-801 ade2-101 trp1-63 his3-200 leu2-1 (24)), BJ2168 (MATa leu2 trp1 ura3-52 prb1-1122 pep4-3 pre1-451 (26)), DBY1 (MAT ura3-52 lys2-801 ade2-101 trp1-63 his3-200 leu2-1 mck1::hisG (11)), and JCY100 (MATa ura3-52 leu2::hisG trp1::hisG his3::hisG (27, 28)).

Strains TRYBJm (MATa leu2 trp1 ura3-52 prb1-1122 pep4-3 pre1-451 mck1::hisG) and JCYmck1 (MATa ura3-52 leu2::hisG trp1::hisG his3::hisG mck1::hisG) were constructed by transforming strains BJ2168 and JCY100, respectively, with the 6.3-kb XhoI-XbaI fragment derived from pDD7. The resulting transformants were grown on medium containing 5-fluoroorotic acid to select for the recombination of the hisG repeats and consequent loss of the URA3 marker gene (29). Successful deletion of the MCK1 locus was confirmed by PCR. Strain Y27300 (MATa/ his31/his31 leu20/leu20 lys20/LYS2 MET15/met150 ura30/ura30 bcy1::kanMX4/BCY1) and its corresponding wild-type strain, BY4743 (MATa/ his31/his31 leu20/leu20 met150/MET15 LYS2/lys20 ura30/ura30) were obtained from EUROSCARF (Frankfurt, Germany) (30).

Site-directed Mutagenesis of MCK1-- Mutations were introduced into the MCK1 coding region using a similar approach to that adopted for the original His₆ tagging of this ORF (see above). In each case a pair of PCR primers flanking the ORF were used (5'-ACA GCG GAT CAA AGG TGA-3' and 5'-TAG GAG TTA AGC CCA AG-3'). The various mutants were created using the following PCR primers in conjunction with primers having complementary sequence. The D164A primer was 5'-CGT TTG TCA TCG TGC TAT CAA ACC ATC C-3' and the Y199F primer was 5'-GCC TTC AAT TAG TTT CAT CTG TTC AAG-3'. In each case the PCR product was cleaved with BsaBI and BsrGI and subcloned into the corresponding site in either pDD4 (giving rise to pTRYMU-D164A and pTRYMU-Y199F) or pTRYGMHU (giving rise to pTRYGMHU-D164A and pTRYGMHU-Y199F).

Purification of Mck1p-His₆-- C-terminally His₆-tagged Mck1p was overproduced from plasmid pTRYGMHU transformed into strain TRYBJm. Expression was induced by growing cells for 24 h at 30 °C in 2-liter synthetic complete medium containing 2% galactose. To purify mutant Mck1p, the plasmids pTRYGMHU-D164A or pTRYGMHU-Y199F were substituted for plasmid pTRYGMHU in this initial induction step. Cells were collected by centrifugation, washed, rapidly frozen in liquid nitrogen, and subsequently lysed as described by Kellogg et al. (31). The lysis buffer (buffer A) consisted of 50 mM sodium phosphate, pH 7.5, 145 mM NaCl, and 5 mM imidazole. Following clarification of the lysate by ultracentrifugation, Tween 20 was added to a final concentration of 0.1%. The lysate was passed through a nickel-agarose column (1-ml bed volume) previously equilibrated in buffer A. The flow-through from the column was discarded, and the column was washed with ten volumes of buffer A. A second wash was performed with six column volumes of buffer A containing 20 mM imidazole. The Mck1 protein was then eluted with three column volumes each of buffer A containing 50 and 100 mM imidazole. These final fractions were assayed for protein concentration using a Bradford-based assay (32) and checked for Mck1p content by SDS-PAGE (33) and Western blotting (34). Peak fractions were pooled and dialyzed overnight against buffer B (50 mM MES, pH 6.5, 1 mM EDTA, 25% glycerol). The protein was then further purified by running the dialysate over an S-Sepharose column (1-ml bed volume) equilibrated in buffer B. The column was washed with ten volumes of buffer B and a further five volumes of buffer B containing 100 mM NaCl. Purified Mck1p was then eluted using buffer B containing increasing concentrations of NaCl. Mck1p typically eluted in the range of 300-400 mM NaCl. Fractions were assayed by SDS-PAGE followed by silver staining or Western blotting. Western blotted membranes were probed with anti-Mck1p (2) or anti-His₆ tag antibodies.

Purification of Tpk1p-His₆-- The procedure for purifying PKA subunits from yeast was based on the work of Hixson and Krebs (35). Tpk1p, His₆-tagged at its C terminus, was overproduced in strain BJ2168 using the 2-µm plasmid pTRYAT1HL, which expresses His₆-tagged Tpk1p under the control of the constitutive ADH1 promoter. The regulatory subunit Bcy1p was co-overproduced with His₆-tagged Tpk1p using a second 2-µm plasmid, YEpBCY1, which expresses BCY1 under the control of its own promoter. Such co-overexpression has been previously found to enhance TPK1 expression (36). Cells were harvested from a 2-liter culture and lysed as described for the purification of Mck1p. The cells were lysed into 50 mM MOPS, pH 7.5, 1 mM EDTA. The lysate was fractionated by adding ammonium sulfate to 40% saturation. The precipitate was resuspended in 50 mM MOPS, pH 7.5, with 0.1% Tween 20. This fraction was loaded onto a nickel-agarose column (1-ml bed volume) equilibrated in 50 mM MOPS, pH 7.5. This buffer was used throughout the nickel-agarose column chromatography with increasing amounts of imidazole added. The column was washed with ten volumes of buffer containing 5 mM imidazole followed by a further six column volumes with 20 mM imidazole. The proteins were eluted in buffer containing 50-100 mM imidazole. Both here and subsequently, fractions were assayed for Tpk1p content by Western blotting with an anti-His₆ tag antibody. Peak fractions were pooled and loaded onto a DEAE-Sephadex column (0.5-ml bed volume) equilibrated with 50 mM MOPS, pH 7.5, 1 mM EDTA. Again, this buffer was used throughout this anion exchange chromatography step, with varying concentrations of NaCl added. The column was washed with 10 volumes of buffer, and the protein was eluted with increasing concentrations of NaCl in the same MOPS buffer. Fractions were assayed by immunoblotting for the His₆ tag, and peak fractions (typically in the range 100-200 mM NaCl) were pooled. The pooled fractions were dialyzed overnight in buffer B (50 mM MES, pH 6.5, 1 mM EDTA, 25% glycerol, as for the purification of Mck1p) and applied to a CM-Sephadex column (0.5-ml bed volume) equilibrated in the same buffer. The column was washed in 10 volumes of buffer before the protein was eluted with increasing concentrations of NaCl in buffer B. The 100-200 mM NaCl fractions were found to contain two SDS-PAGE bands by silver staining (Fig. 1). The higher molecular weight band was found to cross-react with the anti-His₆ tag antibody. The lower band could be removed from the fraction by a brief binding step to cAMP-agarose (50-µl bed volume per 200-µl sample volume). These observations, combined with subsequent kinase assays using Kemptide as a substrate, identified these two bands as Tpk1p and Bcy1p, respectively.

Enzyme Assays-- Mck1p autophosphorylation was assayed using the procedure described by Lim et al. (3). Mck1p tyrosine phosphorylation was assayed by Western blotting using the anti-phosphotyrosine monoclonal antibody clone 4G10 as described by Zhan et al. (37). Phosphotransferase activity of Mck1p or Tpk1p was measured in a similar manner to that described by Lim et al. (3), with minor modifications. To measure Mck1p activity toward exogenous substrates, purified Mck1p was incubated in reaction buffer (10 mM MgCl₂, 50 mM Tris-HCl) with 20 µM [-³²P]ATP (approximately 800 Ci/mol) and 1 µg of myelin basic protein (MBP). The reactions were incubated for between 15 and 30 min at 30 °C before being quenched by addition of sample buffer and boiling, prior to analysis by SDS-PAGE.

The assay for Tpk1p activity toward pyruvate kinase was conducted in an essentially identical fashion to the assay for Mck1p activity toward MBP. Between 2 and 5 µg of purified pyruvate kinase was used as a substrate in these assays, in place of MBP. Approximately 5 ng of Tpk1p was used per reaction, and 170 ng of Mck1p was added during studies of its inhibitory activity. The total reaction volume was 10 µl. Reactions were quenched by addition of an equal volume of reaction buffer, and half of the total reaction volume was analyzed by SDS-PAGE. Adenosine 3':5' cyclic monophosphate (cAMP) was added to reactions as indicated to a final concentration of 10 µM. PKA phosphorylation of its synthetic substrate, Kemptide (amino acid sequence LRRASLG), was assayed as described by Toda et al. (38). Synthetic mammalian protein kinase inhibitor peptide (PKI, amino acid sequence TTYADFIASGRTGRRNAIHD) was added to reactions where indicated (1 µg per reaction).

Assays of pyruvate kinase activity were performed using an assay coupled to L-lactate dehydrogenase as described by Jurica et al. (39). Cell extracts were assayed for protein concentration using a Bradford-based assay (32).

Invasive Growth Assay-- Invasive growth of yeast cells on agar plates was measured using a plate adhesion assay (40). Cells were streaked onto YPD or synthetic minimal solid medium and allowed to grow for 3-5 days. The plates were photographed before and after washing under a stream of running water.

	RESULTS

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Mck1p Does Not Phosphorylate Pyruvate Kinase in Vitro-- The results of Brazill et al. (11) suggested that Mck1p might down-regulate pyruvate kinase by direct phosphorylation. We set out to determine if purified Mck1p phosphorylates purified pyruvate kinase in vitro. Mck1p was purified to homogeneity (Fig. 1) using a C-terminal His₆ tag, a nickel-agarose column, and cation exchange chromatography. The purified enzyme retained catalytic activity toward myelin basic protein (MBP) (Fig. 4) and had a K_m for ATP of 70 µM, comparable to that previously determined for the untagged enzyme (27 µM in Dailey et al. (2); 70 µM in Lim et al. (3)). Purified Mck1p did not phosphorylate purified pyruvate kinase in vitro.² These data raise the possibility that Mck1p does not regulate pyruvate kinase directly but instead acts on this key metabolic enzyme through an intermediary protein kinase.

View larger version (21K): [in this window] [in a new window]   Fig. 1.   Purification of Mck1p, Tpk1p, and Cdc19p. Mck1p and Tpk1p were purified as described under "Experimental Procedures." Purified Cdc19p was a gift from Tom Nowak and Barry Stoddard. The purity of the proteins was determined by SDS-PAGE followed by silver staining.

We found that pyruvate kinase is phosphorylated by an unknown protein kinase in a partially purified preparation of the enzyme.² Mck1p was absent from this pyruvate kinase sample, as determined by immunoblotting.² Because PKA is known to phosphorylate and regulate pyruvate kinase in other organisms (41-43), we examined the effect of adding cAMP on phosphorylation of partially purified pyruvate kinase. We found that cAMP strongly stimulated phosphorylation of the enzyme.² This phosphorylation was inhibited by the addition of purified Mck1p to the reaction.² This led us to postulate that PKA, directly or indirectly, phosphorylates pyruvate kinase in partially purified preparations. Mck1p is capable of inhibiting this PKA-dependent phosphorylation.

Tpk1p Phosphorylates Pyruvate Kinase in Vitro-- We set out to determine if purified PKA is capable of phosphorylating purified pyruvate kinase in vitro. The PKA catalytic subunit Tpk1p was purified as a complex with its regulatory subunit Bcy1p. It has previously been found that efficient production of Tpk1p by the TPK1 gene requires the co-overexpression of the gene encoding Bcy1p (36). Strains used during this study for the overproduction of Tpk1p, therefore, used a BCY1-overexpression plasmid, YEpBCY1, to boost the expression of TPK1. Tpk1p, tagged on its C terminus with a His₆ epitope, was initially purified as a complex with Bcy1p as described under "Experimental Procedures." This protocol yielded a purified complex of Tpk1p with Bcy1p as judged by silver staining of an SDS-PAGE gel (Fig. 1).

The purified PKA complex was assayed for its ability to phosphorylate purified pyruvate kinase in vitro. As shown in Fig. 2A, we found that pyruvate kinase can indeed be phosphorylated by a purified preparation of Tpk1p·Bcy1p complex. This observation suggests that PKA is sufficient to phosphorylate pyruvate kinase in vitro. Tpk1p·Bcy1p complex is known to be catalytically inactive (44). We therefore attribute the activity observed in the above experiment to be due to a small amount of free Tpk1p in our preparation of the complex.

View larger version (23K): [in this window] [in a new window]   Fig. 2.   Pyruvate kinase is phosphorylated by Tpk1p, and this phosphorylation is inhibited by Mck1p in vitro via a mechanism dependent on Mck1p kinase activity. A, purified Cdc19p was phosphorylated by purified Tpk1p·Bcy1p complex in a cAMP-dependent manner. Addition of mammalian PKI or Mck1p to the reaction inhibited this activity. B, similar inhibitory effects of PKI and Mck1p are seen when purified Tpk1p is used to phosphorylate Cdc19p in the absence of Bcy1p. C, Mck1p catalytic activity is required for inhibition of Tpk1p. Purified samples of wild-type or catalytically inactive (D164A) Mck1p were added to reactions to assess their ability to inhibit Tpk1p. Cdc19p was present as the substrate in each assay (A-C). The quantity of each enzyme used in these assays was kept constant throughout, as described under "Experimental Procedures."

If PKA can indeed phosphorylate purified pyruvate kinase, addition of cAMP should stimulate this phosphorylation. We found that adding cAMP to our assays dramatically increased the incorporation of radiolabeled phosphate into pyruvate kinase (Fig. 2A). As an alternative means of stimulating PKA activity, we purified Tpk1p away from the inhibitory Bcy1p regulatory subunit. This was accomplished by using cAMP-conjugated agarose, which specifically binds to the Bcy1p subunit, to dissociate the purified Tpk1p·Bcy1p complex as described under "Experimental Procedures." This step efficiently yielded a homogeneous preparation of Tpk1p, confirmed by silver staining of SDS-PAGE gels (Fig. 1) and Western blotting with anti-His₆ tag monoclonal antibodies.² Subsequent experiments using only the purified Tpk1p subunit to phosphorylate pyruvate kinase demonstrated that Tpk1p on its own is sufficient to phosphorylate pyruvate kinase in vitro (Fig. 2B). Omission of the regulatory Bcy1p subunit from the assays abolished the stimulatory effect of cAMP on the phosphorylation reaction.² These data show that activation of PKA by addition of cAMP or by depletion of the Bcy1p subunit stimulates phosphorylation of pyruvate kinase.

If PKA phosphorylates pyruvate kinase, this phosphorylation should be dependent on PKA activity. We examined the effect of a specific inhibitor of PKA, mammalian protein kinase inhibitor (PKI), on the phosphorylation of pyruvate kinase by the purified preparation of PKA. PKI is a known and specific inhibitor of cAMP-dependent protein kinases (45). PKI was added to assays in which purified Tpk1p·Bcy1p complex was used to phosphorylate pyruvate kinase in the presence of cAMP. Under these conditions, PKI was found to efficiently inhibit the phosphorylation of pyruvate kinase by our PKA preparation (Fig. 2A). This finding shows that the catalytic activity of PKA is required for phosphorylation of pyruvate kinase in our in vitro assays.

These results, taken together, indicate that PKA is capable of directly phosphorylating pyruvate kinase in vitro.

PKA Positively Regulates Pyruvate Kinase in Vivo-- We have shown above that PKA directly phosphorylates pyruvate kinase in vitro. Given that PKA is a known regulator of this enzyme in other organisms (41-43), we investigated the relationship between PKA and pyruvate kinase activities in living yeast. We found that haploid bcy1 cells have higher pyruvate kinase activity than do isogenic wild-type cells.² However, this difference in activity could be an artifact of the slow growth of haploid bcy1 mutants. To circumvent this problem, we took advantage of an accidental observation: Like homozygous bcy1 cells, heterozygous bcy1 diploid cells are unable to sporulate, a phenotype suggestive of PKA activation. Unlike haploid bcy1 cells, heterozygous bcy1 cells do not have a vegetative growth defect. These data suggest that BCY1 is haploinsufficient for sporulation. Consistent with this view, we find that introduction of BCY1 on a plasmid into the heterozygous mutant restores the ability of the strain to sporulate efficiently.² We infer that a heterozygous bcy1 strain has higher PKA activity than wild-type, sufficient to inhibit sporulation but insufficient to slow vegetative growth. As shown in Fig. 3, we find that pyruvate kinase activity is elevated in a heterozygous bcy1 diploid strain. We conclude that PKA is indeed a positive regulator of pyruvate kinase activity in vivo.

View larger version (16K): [in this window] [in a new window]   Fig. 3.   PKA regulates pyruvate kinase in vivo. A BCY1/bcy1 diploid strain (Y27300) has higher pyruvate kinase activity than a homozygous wild-type diploid strain (BY4743). Pyruvate kinase activity in cell extracts was measured using a coupled spectrophotometric assay as described under "Experimental Procedures." The data shown are the results of three independent experiments. Wild-type, ; BCY1/bcy1, .

Mck1p Inhibits the Kinase Activity of Tpk1p in Vitro-- We have shown that Mck1p inhibits the phosphorylation of pyruvate kinase by PKA in partially purified pyruvate kinase samples. To determine if this inhibition is direct, we investigated the effect of adding purified Mck1p to in vitro assays in which purified Tpk1p·Bcy1p was used to phosphorylate purified pyruvate kinase. In each assay PKA was activated by adding cAMP. Addition of purified Mck1p to such assays was found to substantially reduce phosphate incorporation into pyruvate kinase (Fig. 2A). We conclude that Mck1p can directly inhibit the phosphorylation of pyruvate kinase by PKA in vitro.

It is possible that Mck1p does not act directly on the catalytic subunit of PKA but rather prevents cAMP-stimulated dissociation of the inhibitory Bcy1p subunit. To investigate if the inhibition of PKA by Mck1p requires the Bcy1p subunit, we examined the effect of Mck1p on the ability of purified Tpk1p to phosphorylate pyruvate kinase. Mck1p inhibited Tpk1p-dependent phosphorylation of pyruvate kinase both in the presence and absence of the regulatory subunit Bcy1p (Fig. 2, A and B). Thus Mck1p acts directly on the catalytic subunit of PKA.

There are several possible ways in which Mck1p might inhibit phosphorylation of pyruvate kinase by PKA: by inhibiting the catalytic activity of PKA; by altering substrate specificity of the kinase; or by sequestering the substrate, pyruvate kinase. To address the second possibility, we set out to determine if the inhibitory effect of Mck1p was limited to just one substrate for PKA. Assays were performed in which purified Tpk1p was used to phosphorylate Kemptide, a synthetic peptide substrate of PKA, in the presence or absence of Mck1p (Fig. 5B). We observed that Mck1p is capable of inhibiting the PKA-dependent phosphorylation of Kemptide. This observation indicates that Mck1p does not alter the substrate specificity of PKA. These results also allow us to address the possibility that Mck1p might sequester PKA substrates, rendering them unavailable for phosphorylation by PKA. Kemptide was present in massive excess relative to both Mck1p and Tpk1p in the above assays. These data show that Mck1p is unlikely to act by sequestering a particular substrate of PKA. Taken together, we conclude from these results that Mck1p directly inhibits the catalytic activity of PKA in vitro.

Mck1p Requires Catalytic Activity to Inhibit PKA but Does Not Phosphorylate It-- We set out to further investigate the mechanism by which Mck1p inhibits PKA. The simplest possibility is that Mck1p directly phosphorylates Tpk1p. If this mechanism is correct, then the catalytic activity of Mck1p should be required for it to inhibit Tpk1p. We generated a catalytically inactive version of Mck1p (D164A) and purified it to homogeneity as described under "Experimental Procedures." Purified Tpk1p was used to phosphorylate pyruvate kinase or Kemptide in the presence of the purified catalytically inactive Mck1p and cAMP. Under these conditions no inhibition of Tpk1p by Mck1p (D164A) was observed (Figs. 2C and 5). This observation demonstrates that the kinase activity of Mck1p is indeed required for its ability to inhibit Tpk1p in vitro.

However, in all the protein kinase assays so far discussed, Tpk1p was not phosphorylated when catalytically active Mck1p was present, even though Tpk1p was efficiently inhibited under these conditions (Fig. 5A). This surprising observation led us to conclude that Mck1p regulates PKA by a novel mechanism: Mck1p must undergo autophosphorylation before it is capable of binding to and inhibiting Tpk1p. This direct inhibition does not involve phosphorylation of the target.

The Y199F Mutation in Mck1p Abolishes Autophosphorylation on Tyrosine and Is a Separation-of-function Mutant-- This novel mechanism of action of Mck1p points to a critical role for autophosphorylation of the kinase. Comparison of the amino acid sequence of Mck1p with that of other GSK-3 family members suggests a candidate residue upon which the postulated regulatory autophosphorylation may occur. The tyrosine residue at position 199 of Mck1p is highly conserved among GSK-3-related kinases. This residue falls within the so-called "activation loop" of the canonical protein kinase structure. Mutation of this activation-loop tyrosine to phenylalanine in other members of the GSK-3 subfamily (9, 37) compromises phosphotransferase activity with respect to exogenous substrates.

We set out to determine if tyrosine-199 is the site of tyrosine autophosphorylation on Mck1p. A mutant allele encoding Mck1p with its activation-loop tyrosine mutated to phenylalanine (Y199F) was constructed and purified. The autophosphorylation state of the mutant protein was determined in vitro. The activation-loop mutation entirely abolishes the ability of Mck1p to autophosphorylate on tyrosine (Fig. 4). We conclude from this observation that tyrosine-199 is the likely target of autophosphorylation on tyrosine in Mck1p.

View larger version (34K): [in this window] [in a new window]   Fig. 4.   Mutation of activation-loop tyrosine-199 of Mck1p prevents autophosphorylation on tyrosine and abolishes kinase activity toward an exogenous substrate. a, tyrosine autophosphorylation. Purified Mck1p was run on an SDS-PAGE gel, Western-blotted, and probed with anti-phosphotyrosine antibodies. b, SDS-PAGE gel run as in a stained with Coomassie Blue as a control. c and d, Mck1p kinase activity. c, Mck1p autophosphorylation, measured as incorporation of radiolabeled phosphate into Mck1p and (d) Mck1p kinase activity toward an exogenous substrate (MBP) was qualitatively determined as described under "Experimental Procedures." The quantity of each enzyme used in these assays was kept constant throughout, as described under "Experimental Procedures."

To address the possibility that Mck1p can autophosphorylate on residues other than tyrosine, we determined the ability of the activation-loop mutant Mck1p to incorporate radiolabeled phosphate. We found that the activation-loop mutation fails to block Mck1p autophosphorylation entirely, despite abolishing autophosphorylation on tyrosine (Fig. 4). The phosphorylations noted in the above experiment are due to autophosphorylation, because catalytically inactive Mck1p(D164A) is not capable of incorporating radiolabeled phosphate in parallel experiments (Fig. 4). We conclude that the mutant Mck1p(Y199F) is still capable of autophosphorylating on residues other than tyrosine-199.

Because phosphorylation on the activation-loop tyrosine is known to be important for the activity of other yeast GSK-3 enzymes, such as Rim11p, toward exogenous substrates (37, 46), we tested the activity of the Mck1p activation-loop mutant protein toward the exogenous substrate MBP. We found that the activation-loop mutation severely compromises the ability of Mck1p to phosphorylate MBP. This finding indicates that autophosphorylation on tyrosine-199 is important for the kinase activity of Mck1p toward exogenous substrates.

In the previous section, we concluded that inhibition of Tpk1p by Mck1p does not involve phosphorylation of this target. If this mechanism is correct, then we might expect Mck1p(Y199F) to still be competent at inhibiting Tpk1p in vitro. We therefore assayed the ability of the activation-loop mutant Mck1p protein to inhibit phosphorylation of Kemptide or pyruvate kinase by Tpk1p in vitro. In addition, PKA is known to autophosphorylate in vitro (47). Therefore, we also assayed the ability of the activation-loop mutant Mck1p protein to inhibit autophosphorylation of purified Tpk1p·Bcy1p complex. Interestingly, in each case the mutant Mck1p protein was found to inhibit Tpk1p to the same extent as did wild-type Mck1p (Fig. 5). We conclude from this that Mck1p does not require autophosphorylation on tyrosine for its ability to inhibit Tpk1p, but that this autophosphorylation is required for phosphorylation of exogenous substrates. These data independently confirm that Mck1p inhibits Tpk1p by a novel mechanism that does not involve phosphorylation of Tpk1p.

View larger version (26K): [in this window] [in a new window]   Fig. 5.   The activation-loop mutant of Mck1p inhibits Tpk1p in vitro. A, wild-type or mutant Mck1p was added to reactions in which (a) Tpk1p was used to phosphorylate pyruvate kinase, or (b) Tpk1p·Bcy1p complex autophosphorylated in the presence of cAMP. All components were purified (see Fig. 1). B, Kemptide assay. Wild-type or mutant Mck1p was used to inhibit the phosphorylation of the synthetic peptide substrate Kemptide by Tpk1p. The data shown are the results of two independent experiments. The quantity of each enzyme used in these assays was kept constant throughout, as described under "Experimental Procedures."

These results, taken together, show that autophosphorylation of Mck1p on tyrosine-199 is required for phosphorylation of exogenous substrates, but is dispensable for the ability of Mck1p to inhibit Tpk1p. Mck1p thus appears to have two modes of action: autophosphorylation-dependent phosphorylation of exogenous substrates and autophosphorylation-dependent binding to PKA. The Y199F mutation specifically abolishes only the former.

Mck1p Has Two Different Mechanisms of Action in Vivo-- Our in vitro analyses presented above indicate that Mck1p directly inhibits PKA but does not phosphorylate it. Does Mck1p indeed inhibit PKA by such a novel mechanism in vivo? The Y199F mutation severely compromises only the ability of Mck1p to phosphorylate exogenous substrates, having no effect on its ability to inhibit PKA. If our in vitro analysis correctly reflects the situation in vivo, then we predict that the Mck1p(Y199F) should retain some functions in vivo whereas a catalytically inactive mutant should be devoid of function. We therefore determined if the activation-loop mutant mck1(Y199F) and a catalytically inactive mutant mck1(D164A) could complement an mck1 mutant. An mck1 strain was first transformed with a 2-µm plasmid encoding the activation-loop mutant under the control of its own promoter. The wild-type allele expressed from such a construct has previously been found to complement mck1 in vivo (3). The activation-loop mutant gene fully complemented the temperature-sensitive growth defect of mck1 cells (Fig. 6). However, the activation-loop mutant failed to complement the caffeine sensitivity of mck1 cells. We also examined the ability of the catalytically inactive allele to support growth at 37 °C and on medium containing 10 mM caffeine. We found that the catalytically inactive Mck1p was unable to support growth under either condition. We conclude that Mck1p is indeed able to perform some of its functions in vivo without phosphorylating its target protein(s). The catalytic activity of Mck1p is required for its in vivo functions. Therefore, we further conclude that Mck1p acts on one or more targets in vivo by a mechanism that does not involve phosphorylation of the target protein(s) but does require autophosphorylation. Collectively, our in vivo results corroborate our in vitro findings.

View larger version (24K): [in this window] [in a new window]   Fig. 6.   Mck1p acts by two different mechanisms in vivo. Strains in which the chromosomal copy of MCK1 had been deleted (DBY1) were transformed with plasmids overexpressing MCK1 from its own promoter (pDD4, pTRYMU-D164A, and pTRYMU-Y199F) or the empty vector YEp352. Serial dilutions were grown at 37 °C or on medium containing 10 mM caffeine.

The above observations indicate that Mck1p does not have to phosphorylate an exogenous substrate to support growth at 37 °C. Interestingly, either overexpression of the pyruvate kinase gene CDC19 or deletion of BCY1 confers temperature-sensitive growth. These in vivo observations are thus consistent with the activation-loop mutant version of Mck1p retaining the ability to inhibit PKA in vitro and to thereby down-regulate pyruvate kinase.

The Activation-loop Mutant Form of Mck1p Is Competent to Inhibit PKA Activity in Vivo-- Mck1p directly inhibits the activity of PKA in vitro. This inhibition occurs by a novel mechanism involving autophosphorylation-dependent binding but does not involve phosphorylation of PKA subunits. The activation loop mutant form of Mck1p specifically retains the ability to inhibit PKA activity in vitro but is defective in phosphorylation of exogenous substrates. If Mck1p inhibits PKA activity by such a novel mechanism in living cells, then the following should be true: catalytically inactive Mck1p should be unable to inhibit PKA in vivo, but the activation-loop mutant form of Mck1p should be competent for this function.

As we have shown above, pyruvate kinase serves as an in vivo reporter of PKA activity (Fig. 3). Cells carrying the mck1 allele were transformed with 2-µm plasmids encoding either wild-type Mck1p, the catalytically inactive Mck1p, or the activation-loop mutant form of Mck1p. Cell extracts from these strains, and a control strain carrying only the empty vector, were assayed for pyruvate kinase activity. We found that pyruvate kinase activity in the strain expressing wild-type Mck1p is distinctly lower than that found in mck1 cells (Fig. 7A), as had previously been reported (11). In contrast, cells expressing catalytically inactive Mck1p showed a comparable level of pyruvate kinase activity to that of mck1 cells. Strikingly, the pyruvate kinase activity in cells expressing activation-loop mutant Mck1p was indistinguishable from that of cells expressing only the wild-type MCK1 allele. We conclude that there is a direct correlation between the ability of Mck1p to inhibit PKA activity in vitro and the ability of Mck1p to down-regulate pyruvate kinase activity in vivo. We infer that the novel mechanism we have uncovered by which Mck1p inhibits PKA activity in vitro also pertains in vivo.

View larger version (36K): [in this window] [in a new window]   Fig. 7.   The activation-loop mck1 mutant complements mck1 phenotypes associated with increased PKA activity. A, pyruvate kinase activity in extracts from cells carrying different alleles of MCK1. DBY1 cells were transformed with pDD4, pTRYMU-D164A, pTRYMU-Y199F, or the empty vector YEp352. Pyruvate kinase activity in cell extracts was measured using a coupled spectrophotometric assay as described under "Experimental Procedures." The data shown are the results of three independent experiments. Wild-type, ; mck1, ; Y199F, ×; D164A, . B, invasive growth of mck1 strains. JCYmck1 cells were transformed with pDD4, pTRYMU-D164A, pTRYMU-Y199F, or the empty vector YEp352. Invasive growth was measured using a plate adhesion assay as described under "Experimental Procedures."

Hyperactivation of PKA is known to directly promote invasive growth of yeast cells (48, 49). Invasive growth thus serves as another reporter of in vivo PKA activity levels and is independent of pyruvate kinase activity. Cells carrying the mck1 allele, in a strain background competent to undergo invasive growth, were transformed with 2-µm plasmids encoding either wild-type Mck1p, the catalytically inactive Mck1p or the activation-loop mutant form of Mck1p. These transformants, and a control transformed with empty vector alone, were assayed for invasive growth. As shown in Fig. 7B, we found that cells carrying vector alone or expressing only the catalytically inactive form of Mck1p showed robust invasive growth. In contrast, cells expressing wild-type Mck1p or expressing only the activation loop mutant form of Mck1p did not exhibit this phenotype. We conclude that there is a direct correlation between the ability of Mck1p to inhibit PKA activity in vitro and the ability of Mck1p to prevent invasive growth in vivo. These findings further support the likelihood that the novel mechanism we have uncovered by which Mck1p inhibits PKA activity in vitro indeed pertains in vivo.

	DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

We have found that purified, catalytically active, Mck1p cannot phosphorylate purified pyruvate kinase in vitro. Given that Mck1p does regulate pyruvate kinase activity in vivo, the mechanism must be indirect. Here we find that another protein kinase, PKA, mediates the regulation of pyruvate kinase by Mck1p.

Multiple lines of evidence indicate that PKA directly phosphorylates pyruvate kinase. First, purified PKA (Tpk1p·Bcy1p) phosphorylates purified pyruvate kinase in vitro. This phosphorylation is stimulated by addition of cAMP or removal of the Bcy1p inhibitory subunit and is inhibited by PKI, a specific inhibitor of PKA kinase activity. In addition, PKA stimulates phosphorylation of pyruvate kinase in a partially purified preparation of the latter enzyme, indicating some specificity to the reaction. Finally, we found that purified Tpk1p alone phosphorylates purified pyruvate kinase in vitro. Encouragingly, Cytrynska et al. (50) recently and independently found that PKA can phosphorylate pyruvate kinase in partially purified preparations.

We believe that PKA is a positive regulator of pyruvate kinase activity in vivo. We have shown that partial activation of PKA, by deletion of one copy of BCY1 in diploid cells, results in increased pyruvate kinase activity in vivo. We found that deletion of BCY1 in haploid cells also results in increased activity of pyruvate kinase.² Finally, the ability of wild-type and mutant forms of Mck1p to directly inhibit PKA activity in vitro correlates with their ability to down-regulate pyruvate kinase activity in vivo. Our findings are consistent with data from multiple other organisms demonstrating that PKA directly phosphorylates and regulates pyruvate kinase (41-43). In addition, Cytrynska et al. (50) have recently reported that pyruvate kinase co-purifies with PKA in yeast.

Our data indicate that Mck1p regulates pyruvate kinase by directly inhibiting PKA in vitro and in vivo. Purified Mck1p inhibits the phosphorylation of purified pyruvate kinase by purified PKA in vitro. Therefore, Mck1p can directly inhibit PKA activity. The capacity of mutant versions of Mck1p to down-regulate pyruvate kinase activity in vivo correlates with their capacity to directly inhibit PKA catalytic activity in vitro. Finally, mck1 mutants share many phenotypes with bcy1 mutants lacking the cAMP-binding and inhibitory subunit of PKA. Both mutants are temperature-sensitive for growth, both grow poorly on non-fermentable carbon sources, both display constitutive invasive growth, and both display high pyruvate kinase activity. Thus Mck1p, like Bcy1p, behaves genetically and biochemically as an inhibitor of PKA.

Although we have only examined the regulation of Tpk1p by Mck1p in vitro, it is likely that Mck1p modulates the activity of all three catalytic subunits of PKA in vivo. Tpk1p, Tpk2p, and Tpk3p display a high degree of amino acid sequence identity and functional redundancy in vivo (14, 15). Our results in combination with those of Cytrynska et al. (50) indicate that both Tpk1p and Tpk2p can phosphorylate pyruvate kinase. Deletion of MCK1 mimics deletion of BCY1 in preventing growth at high temperature and on non-fermentable carbon sources; i.e., phenotypes that are attributed to activation of all three catalytic subunits of PKA. Finally, deletion of BCY1 or MCK1 promotes invasive growth, a phenotype caused specifically by activation of Tpk2p.

Mck1p acts directly on the PKA catalytic subunit, because purified Mck1p can inhibit purified Tpk1p alone. Mck1p does not act by grossly altering the substrate specificity of PKA or by sequestration of its peptide/protein substrates because Mck1p inhibits the capacity of PKA to phosphorylate both pyruvate kinase (a globular protein) and Kemptide (a peptide) and these inhibitions occur even when the substrates are present in massive excess over the kinases.

The simplest mechanism by which Mck1p might inhibit PKA activity is by phosphorylating PKA. Indeed, the catalytic activity of Mck1p is required for its capacity to inhibit purified Tpk1p. However, we have found that PKA subunits are not phosphorylated by Mck1p even though PKA activity is inhibited by this kinase in vitro. In agreement with this somewhat surprising observation, failure of Mck1p to autophosphorylate on tyrosine compromises its ability to phosphorylate exogenous substrates but does not compromise the capacity of Mck1p to inhibit PKA in vitro or in vivo. Mck1p evidently acts on PKA by a mechanism unusual for protein kinases. Autophosphorylated Mck1p most likely binds to and directly inhibits the catalytic subunits of PKA without intermolecular transfer of phosphate. We have attempted to detect direct physical interaction between Mck1p and PKA catalytic subunits in vitro but have been unsuccessful to date. The interaction may be too weak to survive our manipulations. Despite this failure to detect a direct biochemical interaction between Mck1p and Tpk1p, the interaction almost certainly occurs. Purified Mck1p inhibits purified Tpk1p in vitro demonstrating that the inhibition is direct. The inhibition does not involve sequestration of the peptide/protein substrate. Finally, the inhibition is not due to sequestration of ATP, because ATP is present in massive excess in our experiments (see "Experimental Procedures").

Efficient inhibition of purified Tpk1p by purified Mck1p in our experiments requires an excess of Mck1p (34 to 1 ratio). We have detected some inhibition of Tpk1p when Mck1p is present at 10-fold excess.² The failure to detect inhibition at lower ratios² may reflect an inherently weak interaction between the proteins. Another possibility is that only a small fraction of Mck1p is autophosphorylated in our purified preparation and is thus competent to bind to and inhibit Tpk1p. Although it is possible that Mck1p inhibits Tpk1p by an as yet unknown additional enzymatic activity, this possibility is highly unlikely. Mck1p contains no domains other than those predicted to constitute a protein kinase, and the protein kinase activity of Mck1p is required for its ability to inhibit Tpk1p. Finally, it is possible that the efficient interaction between Mck1p and Tpk1p in vivo is strengthened by another, as yet unknown, co-factor. Although the requirement for an excess of Mck1p over Tpk1p in our experiments points to some complications, it is not of itself sufficient to challenge our view that Mck1p directly and non-covalently binds to, and inhibits, the catalytic subunits of PKA in vitro and in vivo. Interestingly, GSK-3 activity is required for its effective binding to Axin in mammalian cells (51). Thus, it is possible that autophosphorylation-dependent binding of GSK-3 to its targets is a common mechanism by which GSK-3 enzymes act on their substrates.

Our in vitro observations on the mechanism by which Mck1p inhibits PKA are relevant in vivo. A mutant form of Mck1p that is unable to autophosphorylate on tyrosine, Mck1p(Y199F), and cannot phosphorylate exogenous substrates, is competent to inhibit PKA in vitro and in vivo. Mck1p(Y199F) does not, however, complement all the phenotypes of mck1 cells. Mck1p evidently acts by two distinct and genetically separable mechanisms: phosphorylation of some target proteins and autophosphorylation-dependent binding to PKA without intermolecular transfer of phosphate.

PKA is the canonical protein kinase. It was the first protein kinase to have its structure solved, and decades of research have illuminated its mode of action and regulation. To date, PKA has only been known to be regulated by cAMP binding to Bcy1p causing that subunit to dissociate from the catalytic subunits and thereby liberating their catalytic activity. Here we report a second, novel mode of regulation of PKA. Mck1p acts as a direct inhibitor of the liberated catalytic subunits. Thus, in the presence of cAMP, Mck1p acts independently of cAMP and Bcy1p to regulate the activity of the catalytic activity of PKA. To date, variation in the cytoplasmic concentration of cAMP has been taken as reflecting the activity state of PKA. Our data suggest that PKA may also be modulated independently of changes in cAMP concentration.

What is the in vivo role of Mck1p? In vegetatively growing cells, Mck1p evidently acts as a partial inhibitor of PKA. Mck1p also appears to be required for proper function of the morphogenic checkpoint (14, 15) and for centromere function, neither of which is known to involve PKA (14, 15). The existence of multiple targets for the kinase in the cell and the diverse range of functions it affects indicate either a global role for Mck1p in vivo or targeting of Mck1p to a variety of independently regulated pathways. Our understanding of the exact role of Mck1p will be improved by further study of conditions and factors that regulate Mck1p autophosphorylation state and activity.

	ACKNOWLEDGEMENTS

We thank Tom Nowak and Barry Stoddard for generously providing purified pyruvate kinase samples for this study. We also thank Midori Harris, Sue Krause, and G. Steven Martin for helpful discussions.

	FOOTNOTES

^* This work was supported by a Wellcome Trust Prize Travelling Research Fellowship (Grants 054541/Z/98/Z, to T. F. R., and 05454l/B/98/Z, to J. T.) and by National Institutes of Health Grant GM21841 (to J. T.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

^¶ To whom correspondence should be addressed. Tel.: 44(0)141-330-6235; Fax: 44(0)141-330-4878; E-mail: t.rayner@bio.gla.ac.uk.

Published, JBC Papers in Press, March 4, 2002, DOI 10.1074/jbc.M112349200

² T. F. R., unpublished observation.

	ABBREVIATIONS

The abbreviations used are: GSK-3, glycogen synthase kinase-3; PKA, cAMP-dependent protein kinase; MBP, myelin basic protein; PKI, mammalian protein kinase inhibitor peptide; ORF, open reading frame; His₆, hexahistidine; MES, 4-morpholineethanesulfonic acid; MOPS, 4-morpholinepropanesulfonic acid.

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES